Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a ...

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

The research arm of Mercedes-Benz in North America, which is focused on delivering personalized, digital experiences for ...

Over $27 million in Department of Defense funding has been awarded for the New York-based Northeast Regional Defense ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

Beauty entrepreneur and mother Emma Lewisham shares a day in her life, from hosting international meetings for her eponymous ...

David Pittman (left), who directs the Engineer Research and Development Center (ERDC) for the U.S. Army Corps of Engineers, ...

In the heart of Page, Arizona, R D’s Drive-In offers a classic, no-frills experience that locals swear by. This family-run burger joint serves up mouthwatering bites, but its real claim to fame is the ...

Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...

Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Moderna shares are down for the second day in a row after the company said it would slash its research and development costs.